GE HealthCare says Alzheimer's drug approval to drive imaging equipment sales
Reuters
Published Jul 25, 2023 08:07AM ET
Updated Jul 25, 2023 11:05AM ET
By Khushi Mandowara
(Reuters) -GE HealthCare Technologies Inc said on Tuesday that the commercial launch of Alzheimer's treatment and related testing for patients would help drive demand for its imaging equipment at hospitals and medical centers next year.
The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed broader coverage for a type of brain scan used in identifying a key Alzheimer's disease protein to determine patients' eligibility for the new treatment.
This will likely be a "profound growth opportunity" for all firms offering PET scans and molecular imaging, CEO Peter Arduini said on a post-earnings call.
The X-ray and ultrasound machine maker raised its annual profit forecast, after beating quarterly earnings estimates as the availability of electronic components improved, allowing the company to increase production and prices for its equipment.
GE HealthCare's second-quarter sales rose 11% as a surge in demand for healthcare services helped drive a recovery in the purchase of capital-intensive equipment.
Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NYSE:ABT), which make medical devices like heart stents and implants, also reported quarterly profits above Wall Street estimates last week as more patients underwent procedures that were delayed due to the pandemic.
GE HealthCare's total quarterly sales of $4.8 billion were in line with analysts' estimates. MRI machines accounted for more than half of those sales, while $839 million came from ultrasound devices.
The company raised its annual adjusted profit forecast by 10 cents at both ends of its range. It now expects a 2023 profit of $3.70 to $3.85 per share, above expectations of $3.74 per share at the mid-point.
Excluding items, GE HealthCare earned 92 cents per share in the quarter, surpassing estimates of 87 cents, according to Refinitiv data.
Shares of the former GE unit rose pared early gains to trade down nearly 2%.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.